About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Study: Baseline Hormone Levels Appear to Predict Survival in Metastatic, Castration-Resistant Prostate Cancer

by Thilaka Ravi on April 4, 2012 at 11:37 PM
Font : A-A+

 Study: Baseline Hormone Levels Appear to Predict Survival in Metastatic, Castration-Resistant Prostate Cancer

Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels. The finding was presented at the AACR Annual Meeting 2012, between March 31 - April 4.

If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with metastatic, castration-resistant prostate cancer, according to Charles J. Ryan, M.D., associate professor of clinical medicine and urology at University of California-San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Calif.

Advertisement

"We have identified that patients who have higher levels of androgen compared with those with lower levels have a better prognosis overall and a better prognosis when receiving abiraterone than patients with lower levels of androgens," said Ryan. "Patients with low hormone levels seem to have a worse prognosis overall; however, they still benefitted significantly from receiving abiraterone as opposed to receiving placebo."

In the past, this form of prostate cancer was referred to as hormone-refractory prostate cancer. However, this term is no longer used because, in recent years, researchers have discovered that certain drugs, like abiraterone, which are essentially hormone therapies, improve outcomes and survival rates.
Advertisement

In this prospective substudy, Ryan and colleagues evaluated data from a randomized phase III trial that compared abiraterone to placebo and led to the approval of abiraterone. They categorized patients according to high levels or low levels of hormones.

The results indicated that higher baseline hormone levels were associated with significantly higher overall survival in patients regardless of initial treatment compared with low baseline levels. Patients assigned to placebo and who had high hormone levels had nearly 50 percent improvement in survival compared with those assigned to placebo and who had low hormone levels. In addition, abiraterone was associated with longer overall survival compared with treatment with placebo in patients with high and low levels of baseline hormones.

Patients assigned to abiraterone who had high baseline levels of hormones had almost twice the overall survival compared with those with low levels of hormones assigned to placebo.

"We used to think that it was not necessary to measure hormone levels once they were below normal - that was in part due to the fact that we were using insensitive assays," Ryan said. "However, now we know that they have prognostic and predictive significance and that physicians treating these patients should think about conducting hormone tests."

According to Ryan, more work is required to determine how these data will inform the standard-of-care management of patients with prostate cancer; however, it is likely that these data will affect the design of future clinical trials.

The study was sponsored by Cougar Biotechnology, which is owned by Johnson & Johnson.



Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Dealing with Menopause symptoms through lifestyle changes 

Most Popular on Medindia

Noscaphene (Noscapine) Blood Donation - Recipients How to Reduce School Bag Weight - Simple Tips Indian Medical Journals Pregnancy Confirmation Calculator Diaphragmatic Hernia Accident and Trauma Care Turmeric Powder - Health Benefits, Uses & Side Effects Find a Doctor Blood Pressure Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Study: Baseline Hormone Levels Appear to Predict Survival in Metastatic, Castration-Resistant Prostate Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests